43624-031-01 : NDC 2026 Code

43624-031-01 : Pembrolizumab And Berahyaluronidase Alfa ( )

Additionally :

You can get information about “43624-031-01” NDC code in 43624-031-01 in HTML format

HTML | 43624-031-01 in TXT (Plain Text) format

TXT | 43624-031-01 in PDF (Portable Document Format)

PDF | 43624-031-01 in XML format

XML formats.

NDC Code : 43624-031-01 – JSON Data Format

                
{
  "NDC": {
    "NDCCode": "43624-031-01",
    "PackageDescription": "130 VIAL in 1 TRAY (43624-031-01)  / 4.8 mL in 1 VIAL",
    "NDC11Code": "43624-0031-01",
    "ProductNDC": "43624-031",
    "ProductTypeName": "DRUG FOR FURTHER PROCESSING",
    "ProprietaryName": null,
    "ProprietaryNameSuffix": null,
    "NonProprietaryName": "Pembrolizumab And Berahyaluronidase Alfa",
    "DosageFormName": "INJECTION, SOLUTION",
    "RouteName": null,
    "StartMarketingDate": "20250919",
    "EndMarketingDate": null,
    "MarketingCategoryName": "DRUG FOR FURTHER PROCESSING",
    "ApplicationNumber": null,
    "LabelerName": "BSP Pharmaceuticals S.p.A.",
    "SubstanceName": "BERAHYALURONIDASE ALFA; PEMBROLIZUMAB",
    "StrengthNumber": "2000; 165",
    "StrengthUnit": "U/mL; mg/mL",
    "Pharm_Classes": null,
    "DEASchedule": null,
    "Status": "Unfinished",
    "LastUpdate": "2025-09-22",
    "PackageNdcExcludeFlag": null,
    "ProductNdcExcludeFlag": null,
    "ListingRecordCertifiedThrough": "20261231",
    "StartMarketingDatePackage": "19-SEP-25",
    "EndMarketingDatePackage": null,
    "SamplePackage": null
  }
}